Metraipolis › archive › dc_651fdb169ecd

Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction — Europe PMC PMID:41551500

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41551500
DOI: 10.3389/fmed.2025.1733918
License (as archived): solo-consultazione
Archived: 2026-11-07T03:00:03.132Z
SHA-256 of the archived text: 1cb60b7a5bf5f6c6a78b4fa6c148e73afb584ede3a8b39106d2198a10fc1003f
Stable URL of this page: https://metraipolis.com/documento/dc_651fdb169ecd

How to cite

Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction — Europe PMC PMID:41551500 — Europe PMC (en), https://europepmc.org/article/MED/41551500 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_651fdb169ecd (Metraipolis archive dc_651fdb169ecd, sha256 1cb60b7a5bf5f6c6a78b4fa6c148e73afb584ede3a8b39106d2198a10fc1003f)

BibTeX

@misc{dc651fdb169ecd,
  title = {Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction — Europe PMC PMID:41551500},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41551500},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_651fdb169ecd; sha256 1cb60b7a5bf5f6c6a78b4fa6c148e73afb584ede3a8b39106d2198a10fc1003f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41551500. Agents can read the archived copy with the MCP tool read_document.